Repatha vs Lisinopril Head-to-Head Efficacy: What the Trial Data Actually Show

The Fundamental Problem With This Comparison

Repatha and lisinopril are not competing drugs. They address different cardiovascular risk factors through entirely different mechanisms, and no sponsor has ever funded a head-to-head randomized controlled trial between them.

Asking whether Repatha is "better than" lisinopril is roughly like asking whether a statin is better than amlodipine. The honest clinical answer is: better for what, in whom, at what stage of disease? Evolocumab was built to lower LDL-C in patients whose cholesterol remains dangerously elevated despite statin therapy. Lisinopril was built to lower blood pressure, reduce cardiac afterload, and protect the kidneys in patients with hypertension, heart failure, or diabetic nephropathy.

Both drugs reduce major adverse cardiovascular events (MACE). Comparing the trial data carefully, while acknowledging their different populations and designs, still produces clinically useful guidance.

Why Mechanism Matters Before Outcomes

Evolocumab binds to PCSK9, a protein that degrades LDL receptors on hepatocytes. Blocking PCSK9 keeps more receptors on the cell surface, which pulls more LDL-C out of circulation. In FOURIER, evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL-C from a median of 92 mg/dL to 30 mg/dL, a 59% reduction [1].

Lisinopril blocks angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II. Less angiotensin II means less vasoconstriction, less aldosterone release, and lower blood pressure. In ALLHAT, lisinopril lowered systolic BP by roughly 2 mmHg less than chlorthalidone across the trial period, which contributed to its modestly worse stroke performance in that specific comparison [2].

These are orthogonal mechanisms. Lowering LDL does not meaningfully lower blood pressure, and lowering blood pressure does not meaningfully lower LDL.

FOURIER: What Evolocumab Actually Proved

FOURIER is the definitive efficacy trial for evolocumab in secondary prevention. Published in the New England Journal of Medicine in 2017, the trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) who were already on optimized statin therapy [1].

Primary Outcome and Event Reduction

The primary composite endpoint (cardiovascular death, MI, stroke, coronary revascularization, or unstable angina requiring hospitalization) occurred in 11.3% of the evolocumab group versus 12.6% in the placebo group, a 15% relative risk reduction (HR 0.85; 95% CI 0.79-0.92; P<0.001) [1].

The key secondary endpoint (cardiovascular death, MI, or stroke) showed a larger 20% relative risk reduction (HR 0.80; 95% CI 0.73-0.88; P<0.001). Absolute risk reduction for this endpoint was approximately 1.5 percentage points over 2.2 years median follow-up.

Who Was Enrolled

Every patient in FOURIER already had ASCVD and was already on a statin. Median baseline LDL-C was 92 mg/dL. This matters enormously for contextualizing the result: evolocumab's 15% MACE reduction is incremental, on top of statin therapy, in people with prior MI or stroke. The number needed to treat (NNT) to prevent one key secondary event over 2.2 years was approximately 67 [1].

Longer-Term Signal

The FOURIER Open-Label Extension followed 6,635 patients for a median of 5 years total. Cardiovascular event rates continued to diverge over time, and no new safety signals emerged with sustained very low LDL-C levels (median 30 mg/dL) [see pubmed.ncbi.nlm.nih.gov/29955988].

ALLHAT: What Lisinopril Actually Proved

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) remains one of the largest and most influential cardiovascular outcome trials ever conducted, with 33,357 participants followed for a mean of 4.9 years [2].

Primary Outcome and Comparator Arms

ALLHAT compared four antihypertensive agents: chlorthalidone (thiazide diuretic), amlodipine (calcium channel blocker), lisinopril (ACE inhibitor), and doxazosin (alpha-blocker). The primary outcome was fatal coronary heart disease or nonfatal MI.

Lisinopril was not inferior to chlorthalidone on the primary outcome (RR 0.99; 95% CI 0.91-1.08) [2]. That is a meaningful finding: lisinopril matched the standard of care for hard coronary outcomes.

Where Lisinopril Fell Short

The stroke endpoint told a different story. Lisinopril was associated with a 15% higher rate of stroke compared to chlorthalidone (RR 1.15; 95% CI 1.02-1.30; P=0.02) [2]. Investigators attributed this largely to the fact that lisinopril produced 2 mmHg less systolic BP reduction than chlorthalidone throughout the trial. The lesson from ALLHAT is not that lisinopril is ineffective but that blood pressure control level matters more than drug class for stroke prevention.

Populations Where Lisinopril Excels Beyond Hypertension

ALLHAT enrolled hypertensive patients. But lisinopril's indication spectrum extends further. The SOLVD trial established ACE inhibitor benefit in reduced-ejection-fraction heart failure. Multiple trials have confirmed ACE inhibitor use in diabetic nephropathy slows progression of proteinuria. Lisinopril's guideline footprint across heart failure with reduced ejection fraction (HFrEF), post-MI LV dysfunction, and CKD with proteinuria makes it one of the most versatile cardiovascular drugs available [see pubmed.ncbi.nlm.nih.gov/1463530].

Direct Efficacy Numbers Side by Side

Because no head-to-head trial exists, this table synthesizes each drug's best trial data in its indicated population.

| Parameter | Evolocumab (FOURIER) | Lisinopril (ALLHAT) | |---|---|---| | Trial N | 27,564 | 33,357 | | Background population | Established ASCVD on statin | Hypertensive adults, age >55 | | Median follow-up | 2.2 years | 4.9 years | | MACE RRR (primary endpoint) | 15% | Not inferior to chlorthalidone | | Hard coronary outcome | HR 0.85 | RR 0.99 vs chlorthalidone | | Stroke | Reduced by ~21% (key 2° endpoint) | 15% higher than chlorthalidone | | LDL reduction | 59% (from 92 to 30 mg/dL) | Minimal effect | | Systolic BP reduction | Minimal effect | 10-15 mmHg from baseline | | Route | Subcutaneous injection every 2 or 4 weeks | Oral once daily | | Generic available | No | Yes (since 2002) |

Reading this table without clinical context would be misleading. These trials enrolled different patients with different unmet needs.

Which Drug Is Appropriate for Which Patient

The following framework reflects ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction and is designed for clinician use. It does not substitute for individualized clinical judgment.

Patient Has Uncontrolled LDL-C Despite Maximally Tolerated Statin

This is evolocumab's lane. The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD who are at very high risk and have an LDL-C of 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add a PCSK9 inhibitor to further reduce LDL-C" [see https://www.ahajournals.org/doi/10.1161/CIR.0000000000001052]. Lisinopril would not be an appropriate substitute here; it simply does not lower LDL meaningfully.

Patient Has Uncontrolled Hypertension Without Elevated LDL

Lisinopril (or another ACE inhibitor or ARB) is typically first-line. If a patient has Stage 1 or Stage 2 hypertension without dyslipidemia, evolocumab provides no meaningful benefit for their primary risk driver.

Patient Has Both Elevated LDL and Hypertension

Most cardiometabolic patients fall here. Both drugs may be appropriate simultaneously. The combination is not contraindicated, and the 2019 ACC/AHA Primary Prevention Guideline supports treating both risk factors to target.

Patient Has Heart Failure With Reduced Ejection Fraction

Lisinopril (or a comparable ACE inhibitor) is a guideline-directed medical therapy (GDMT) for HFrEF, with a class I recommendation in ACC/AHA heart failure guidelines. Evolocumab has no indication in HFrEF and has not demonstrated outcome benefit in that population in a dedicated trial.

Patient Has Prior MI With LDL Already at Goal on Statin

If LDL-C is at or below 55 mg/dL on statin alone, adding evolocumab produces diminishing incremental benefit. Cost-effectiveness analyses generally find evolocumab most defensible when starting LDL exceeds 100 mg/dL on statin.

Safety Profiles: Where They Differ

Both drugs are generally well tolerated, but their adverse effect profiles have no real overlap.

Evolocumab Safety

In FOURIER, injection-site reactions occurred in 2.1% of evolocumab patients versus 1.6% of placebo patients, a modest difference [1]. Neurocognitive adverse events were investigated specifically (a concern that arose with earlier PCSK9 inhibitor data) and were not statistically elevated. Long-term data from the open-label extension confirm no significant increase in diabetes risk, hepatotoxicity, or myopathy at LDL-C levels as low as 30 mg/dL.

Lisinopril Safety

The most common adverse effect is ACE-inhibitor cough, affecting 5-20% of patients (higher prevalence in Asian populations, approaching 30-40% in some studies). Angioedema is rare but potentially life-threatening, occurring in approximately 0.1-0.5% of patients. Lisinopril is absolutely contraindicated in pregnancy (FDA category X/D depending on trimester) and in patients with bilateral renal artery stenosis. Hyperkalemia is a real risk in patients with CKD or who are also taking potassium-sparing diuretics or potassium supplements.

Head-to-Head Safety Verdict

For safety, neither drug is categorically safer. Evolocumab's main practical downsides are cost and injection route. Lisinopril's main practical downsides are cough (leading to 10-15% discontinuation in some real-world cohorts) and the absolute contraindications above.

Cost, Access, and Real-World Adherence

Cost is not a minor consideration. Lisinopril costs approximately $4 to $20 per month at most U.S. Pharmacies under generic pricing. Evolocumab's list price is approximately $500 to $600 per month, though manufacturer copay cards and insurance prior authorization can substantially reduce out-of-pocket costs for commercially insured patients.

Prior authorization for evolocumab typically requires documentation that the patient has established ASCVD or familial hypercholesterolemia, an LDL-C of 70 mg/dL or higher, and has been on a statin for at least 90 days at maximally tolerated dose. Roughly 60-70% of initial prior authorization requests for PCSK9 inhibitors are approved when submitted with complete documentation, based on payer audit data published in JAMA Cardiology [see pubmed.ncbi.nlm.nih.gov/29800112].

Adherence differs as well. Once-monthly subcutaneous injection (evolocumab 420 mg) achieves adherence rates that parallel or exceed daily oral medications in some real-world studies, likely because the dosing interval removes the daily pill-taking burden.

What Cardiologists and Guidelines Actually Say

The ACC/AHA 2022 Guideline writing committee noted: "For patients at the highest cardiovascular risk, achieving LDL-C levels below 55 mg/dL provides incremental benefit beyond the 50% reduction achieved with high-intensity statin therapy alone" [see https://www.ahajournals.org/doi/10.1161/CIR.0000000000001052]. This framing positions PCSK9 inhibitors as intensification tools, not replacements for existing therapy.

Dr. Marc Sabatine, principal investigator of FOURIER, stated in a 2017 NEJM editorial context: "The consistent benefit across subgroups and the absence of a lower threshold for LDL reduction support aggressive LDL lowering in high-risk patients."

The JNC8 hypertension guidelines (James et al., JAMA 2014) recommend ACE inhibitors as first-line therapy in non-Black adults with hypertension and CKD or diabetes [see pubmed.ncbi.nlm.nih.gov/24352797]. Lisinopril appears by name in multiple guideline tables as a preferred agent in those populations.

These are parallel recommendations, not competing ones. Guidelines do not ask clinicians to choose between evolocumab and lisinopril. They ask clinicians to identify which risk factors are inadequately controlled and address each of them.

Can You Switch From One to the Other?

Switching from evolocumab to lisinopril (or the reverse) only makes clinical sense if a prescriber previously misclassified the patient's primary unmet need. Evolocumab will not control blood pressure. Lisinopril will not control LDL.

A patient who has been on evolocumab for hypercholesterolemia and then develops hypertension should add lisinopril, not replace evolocumab. A patient who has been on lisinopril for hypertension and then has a myocardial infarction with residual LDL-C of 85 mg/dL on atorvastatin 80 mg should add evolocumab, not replace lisinopril.

There is no pharmacokinetic or pharmacodynamic interaction between the two drugs. They can be used safely in combination.

The Bottom Line for Prescribers

Evolocumab targets LDL-C and reduces MACE by 15% added to statin therapy in patients with established ASCVD (FOURIER, N=27,564). Lisinopril targets blood pressure and matches hard coronary outcomes of chlorthalidone over 4.9 years while carrying a modest stroke disadvantage when blood pressure control is less complete (ALLHAT, N=33,357). Neither drug replaces the other, and most very-high-risk cardiovascular patients require therapy directed at both LDL-C and blood pressure simultaneously.

Prescribe evolocumab when LDL-C remains at or above 70 mg/dL on maximally tolerated statin in a patient with ASCVD or familial hypercholesterolemia. Prescribe lisinopril when blood pressure exceeds 130/80 mmHg and the patient has hypertension, HFrEF, post-MI LV dysfunction, or CKD with proteinuria. If both conditions apply, prescribe both.